Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
InnoCare Pharma Ltd. ( (HK:9969) ) has issued an announcement.
InnoCare Pharma Limited has released its unaudited financial data for the first quarter of 2025, prepared according to Chinese accounting principles and the STAR Market requirements of the Shanghai Stock Exchange. The announcement advises shareholders and potential investors to exercise caution when dealing with the company’s securities, as the data has not been reviewed by independent auditors.
The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on developing treatments for cancer and autoimmune diseases. The company is listed on the Stock Exchange of Hong Kong and operates in the pharmaceutical industry, with a market focus on innovative therapies.
Average Trading Volume: 14,004,471
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.24B
Learn more about 9969 stock on TipRanks’ Stock Analysis page.